The story of Viagra and its creator , copyright, presents a fascinating picture for cautious investors. While the iconic drug initially fueled enormous earnings, its exclusivity has expired , leading to rival alternatives flooding the arena. This decline in cost presents a real obstacle for copyright and any company considering a large holding in t